Mark Deponte, MD
Family Medicine · Lisbon, CTNPI 1265434583
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 509 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 509 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- GSK$1K
- AstraZeneca$704
- Astellas Pharma US Inc$478
- Pfizer$456
- plus $2K from 19 others
What the payments were for
- Food & beverage$8,22499%
- Education$891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 115 | $1,782 |
| Novo Nordisk | 102 | $1,366 |
| GSK | 80 | $1,281 |
| AstraZeneca(2 entities) | 36 | $704 |
| Astellas Pharma US Inc | 20 | $478 |
| Pfizer | 29 | $456 |
| Otsuka America Pharmaceutical, Inc. | 20 | $365 |
| Boehringer Ingelheim | 14 | $263 |
| Lundbeck LLC | 10 | $237 |
| Amgen | 12 | $202 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $193 |
| Eisai Inc. | 12 | $143 |
| Merck | 9 | $137 |
| Novartis | 7 | $128 |
| Phathom Pharmaceuticals, Inc. | 6 | $111 |
| Exact Sciences | 5 | $100 |
| Endo Pharmaceuticals Inc. | 5 | $96 |
| Biohaven Pharmaceuticals, Inc. | 4 | $68 |
| Abbott | 3 | $60 |
| Corcept Therapeutics | 2 | $49 |
| Amarin Pharma, Inc. | 2 | $33 |
| Lilly USA, LLC | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
How this compares
$8,313 in reported general payments places this provider in the 90th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 115 | $168,580 |
| JardianceEmpagliflozin | 136 | $151,831 |
| JanuviaSitagliptin Phosphate | 55 | $75,277 |
| EliquisApixaban | 86 | $65,336 |
| OtezlaApremilast | 13 | $60,674 |
| XareltoRivaroxaban | 42 | $53,162 |
| EntrestoSacubitril/Valsartan | 18 | $24,684 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $23,457 |
| LinzessLinaclotide | 30 | $23,432 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $20,925 |
| MounjaroTirzepatide | 17 | $19,874 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 49 | $14,830 |
| Dexlansoprazole DrDexlansoprazole | 37 | $13,829 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $13,816 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $12,905 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,366 | $168,580115 claims |
| Boehringer IngelheimJardiance, Tradjenta | $263 | $162,987157 claims |
| MerckJanuvia, Janumet | $137 | $86,35066 claims |
| PfizerEliquis | $456 | $65,33686 claims |
| AmgenOtezla | $202 | $60,67413 claims |
| Johnson & JohnsonXarelto | $16 | $53,16242 claims |
| GSKTrelegy Ellipta, Arexvy, Anoro Ellipta, Shingrix | $1,281 | $53,109104 claims |
| AbbVieLinzess, Synthroid | $1,782 | $27,38886 claims |
| NovartisEntresto | $128 | $24,68418 claims |
| Lilly USA, LLCMounjaro | $17 | $19,87417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Lisbon
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
- Helar CamposNew London$29K
- Kristin GianniniVernon$28K
- Sanjeev RaoBridgeport$27K
- Michael BeyVernon Rockville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.